Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | PDE9A | O76083 | 7/20 | 0.39 |
| ▸ | PDE1A | P54750 | 2/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366723 | 0.86 | AR (0.39) | ARPDE9APDE1APDE1BPDE1C | |
| SCHEMBL3492585 | 0.86 | PDE1A (0.56) | PDE9APDE1APDE1BPDE1CCYP2C9 | |
| SCHEMBL6366319 | 0.84 | KDM4E (0.48) | ARPDE9APDE1APDE1BPDE1C | |
| SCHEMBL6366854 | 0.84 | CCR2 (0.39) | ARPDE9APDE1APDE1BPDE1C | |
| SCHEMBL6365889 | 0.82 | PNP (0.44) | ARPDE9APDE1APDE1BPDE1C | |
| SCHEMBL6371852 | 0.81 | PDE2A (0.39) | — | |
| SCHEMBL6366302 | 0.80 | PDE1A (0.41) | PDE9APDE1APDE1BPDE1CSLC6A2 | |
| SCHEMBL6374090 | 0.80 | PDE1A (0.48) | PDE9APDE1APDE1BPDE1C | |
| SCHEMBL6367367 | 0.79 | CXCR2 (0.32) | PDE1APDE1BPDE1C | |
| SCHEMBL6368262 | 0.79 | CXCR2 (0.38) | ARPDE9APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | AR 816/4885PDE9A 3/4885PDE1A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.